Zokovea (ensitrelvir)

Where it stands

Zokovea (ensitrelvir) is authorised in the EU. The European Commission decision of 18 September 2026 granted the marketing authorisation to Shionogi B.V. The CHMP had issued a positive opinion on 23 June 2026, so about 87 days (roughly 12 weeks) passed between the opinion and the EC decision.

The authorised indication is post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older. The records describe this as a prevention use after exposure. They do not mention treatment of established infection in the EU.

The records also list Xocova (the same substance) as approved in the US. They give no indication, approval date or labelling for it. A comparison of the EU and US positions would need the US label, and none is provided here.

Regulatory pathway and designations

The records show two milestones: a CHMP positive opinion (23 June 2026) and the EC approval decision (18 September 2026). This is the standard sequence in the centralised procedure. The CHMP gives a scientific opinion, and the Commission then issues the legally binding decision for all EU Member States.

The only designation listed is additional monitoring. The records do not say whether the authorisation is standard or conditional, whether accelerated assessment or exceptional circumstances applied, or whether orphan or PRIME-type status was involved. They also give no post-authorisation conditions or obligations, so none should be assumed.

The marketing authorisation holder is Shionogi B.V. The records say nothing about the clinical package supporting the prophylaxis indication, so this analysis does not comment on the evidence base.

Safety and pharmacovigilance

Additional monitoring means the product is subject to intensified safety surveillance. It is identified by a black inverted triangle in the product information, with a standard statement inviting healthcare professionals and patients to report suspected adverse reactions. The status is often applied to newly authorised active substances, but the records do not state why it applies to Zokovea.

The records contain no safety data. They give no adverse reaction profile, contraindications, drug-interaction warnings or risk management plan details, so none can be described here. Anyone assessing the product's safety should consult the EU product information (SmPC) and the EPAR.

Practically, the designation means that spontaneous reporting from EU use after launch will matter for the product's safety profile. Marketing authorisation holders and national authorities will be watching these reports.

What to watch

The records give no launch timing, national reimbursement or pricing status, or post-authorisation commitments. Those would need to be checked against national and EMA sources.

Useful items to follow are the published EPAR and SmPC, which would clarify the evidence behind the prophylaxis indication and any risk-minimisation measures. Also worth following are the safety updates that come with additional monitoring and any later variations to the indication.

For a cross-regional view, the US Xocova label should be compared with the EU wording, since the records confirm US approval but give no details.